Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879652 | 0.84 | TSHR (0.38) | NEK1IMPDH2IMPDH1DYRK1AKDM4E | |
| SCHEMBL4804959 | 0.84 | NEK1 (0.34) | NEK1IMPDH2IMPDH1DYRK1A | |
| SCHEMBL1363857 | 0.84 | TRPV4 (0.37) | NEK1DYRK1ACYP2A6 | |
| SCHEMBL3606665 | 0.84 | NEK1 (0.34) | NEK1DYRK1A | |
| SCHEMBL24946535 | 0.79 | NEK1 (0.34) | NEK1IMPDH2IMPDH1KDM4EALDH1A1 | |
| SCHEMBL4802256 | 0.79 | IMPDH2 (0.54) | IMPDH2IMPDH1KDM4EALDH1A1MAPT | |
| SCHEMBL29558893 | 0.79 | NEK1 (0.34) | NEK1IMPDH2IMPDH1KDM4EALDH1A1 | |
| SCHEMBL3602206 | 0.79 | IMPDH2 (0.54) | IMPDH2IMPDH1KDM4EALDH1A1MAPT | |
| SCHEMBL3604859 | 0.74 | AR (0.56) | KDM4EALDH1A1MAPTAR | |
| SCHEMBL22122277 | 0.72 | CSNK2A2 (0.37) | NEK1IMPDH2IMPDH1ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407619-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | NEK1 1552/4885IMPDH2 4164/4885IMPDH1 4115/4885 |
| US-10407619-B2 | Liquid crystal composition | RCC1, CCDC47, ACIN1 | NEK1 1552/4885IMPDH2 4164/4885IMPDH1 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.